1. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects.
- Author
-
Jacobs M, Van Eeckhoutte HP, Wijnant SRA, Janssens W, Joos GF, Brusselle GG, and Bracke KR
- Subjects
- Angiotensin-Converting Enzyme 2, Belgium, Biomarkers blood, Biopsy, Needle, Cross-Sectional Studies, Female, Humans, Immunohistochemistry, In Vitro Techniques, Linear Models, Male, Multivariate Analysis, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive epidemiology, Real-Time Polymerase Chain Reaction methods, Respiratory Mucosa metabolism, SARS-CoV-2, Sensitivity and Specificity, Smoking blood, Specimen Handling, Statistics, Nonparametric, Betacoronavirus metabolism, Peptidyl-Dipeptidase A metabolism, Pulmonary Disease, Chronic Obstructive pathology, RNA, Messenger blood, Respiratory Mucosa pathology, Smoking epidemiology
- Abstract
Competing Interests: Conflict of interest: M. Jacobs has nothing to disclose. Conflict of interest: H.P. Van Eeckhoutte has nothing to disclose. Conflict of interest: S.R.A. Wijnant has nothing to disclose. Conflict of interest: G.F. Joos reports grants from AstraZeneca and Chiesi, personal fees for consultancy from Bayer and Eureca vzw, grants and personal fees for lectures and consultancy from GlaxoSmithKline, personal fees for lectures from Teva, outside the submitted work; all fees were paid to the department. Conflict of interest: W. Janssens reports grants from AstraZeneca and Chiesi. Conflict of interest: G.G. Brusselle reports personal fees for advisory board work and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work. Conflict of interest: K.R. Bracke has nothing to disclose.
- Published
- 2020
- Full Text
- View/download PDF